Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apnea
Sponsor: Jazz Pharmaceuticals
Listed as NCT02806895, this PHASE2 trial focuses on Excessive Sleepiness and Obstructive Sleep Apnea and remains completed. Sponsored by Jazz Pharmaceuticals, it has been updated 10 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Feb 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2018 — Feb 2020 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jazz Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .